Andrew Foxley, VP - R&D Franchise Head at AstraZeneca, joins the Board

Andrew Foxley, VP - R&D Franchise Head at AstraZeneca, joins the Board:
Our Chairman Florian Kemmerich and CEO Su Metcalfe are delighted to announce Andrew Foxley's joining the Board of LIFNanoRx as Advisor. Andrew brings a wealth of experience in Clinical development of new therapies - strongly complimenting the Board's strength in Regulatory Affairs with Alan Boyd and Clinical Product Manufacture with Andrew Carver.

https://www.astrazeneca.com/our-company/our-people/andrew-foxley.html
https://www.boydconsultants.com/professor-boyd-awarded-fellowship-of-the-academy-of-medical-sciences/
https://www.linkedin.com/in/asc/?originalSubdomain=uk